Search academic texts

Information × Registration Number 0223U002359, 0120U002186 , R & D reports Title Optimization of conservative treatment of HER2 / neu breast cancer patients (negative) at high risk of disease progression. popup.stage_title Head Syvak Lubov А., Доктор медичних наук Registration Date 15-02-2023 Organization National Cancer Institute popup.description2 The object of the study is 195 breast cancer patients, 136 patients with luminal B breast cancer and 59 patients with triple negative breast cancer. The aim of the work is to increase the effectiveness of treatment of patients with Her2/neu negative breast cancer by optimizing complex treatment taking into account the molecular genetic characteristics of the tumor. It is scientifically proven that a high level of CD4+ lymphocytes in a tumor before treatment increases the risk of its metastasis by 1.63 times (HR 1.63; 95% CI = 1.21–2.32; p = 0.001), and a high level of FOXP3+ lymphocytes - indicates a decrease in the probability of disease recurrence (HR 0.69; 95% CI = 0.50–0.84; p = 0.005) in patients with estrogen-negative Her2/neu-negative breast cancer. The independent prognostic value of FOXP3+ lymphocytes in the residual tumor after completion of NHT in patients with locally advanced luminal Her2/neu negative breast cancer was scientifically confirmed (RR = 1.18; CI 95%, 1.01–1.39). For the first time, it has been proven that the risk of disease recurrence in patients with luminal Her2/neu negative breast cancer is associated with 4 factors: the level of FOXP3+, the Ki-67 index in the residual tumor, the number of affected axillary lymph nodes after neoadjuvant polychemotherapy and the volume viable tumor parenchyma. For the first time, it was determined that an increase in the number of intratumoral and stromal CD8+ lymphocytes in the residual tumor after NHT significantly reduces the risk of disease recurrence, HR 0.7 (95% CI 0.4–0.9; p = 0.01) and HR 0.65 (95% CI 0.5–0.9; p = 0.02), respectively. For the first time, it was scientifically proven that the level of therapeutic pathomorphosis was better in patients with the N/del32 genotype for the CCR5 gene. The average values of CPR in carriers of the N/N allele of the CCR5 gene were 52.94 ± 4.06%, and in carriers of the N/del32 allele of the CCR5 gene – 35.63 ± 7.37% (р=0.04). Product Description popup.authors Verʹovkina Natalya O. Dasiukevich Olga Y. Lyalkin Serhii А. Martynyuk Olena M. Orel Valery Е. Rykhalskyy Oleksandr Yu Tarasenko Tetyana Y. Filchakov Feodosius V. Yatsenko Lyudmila D. popup.nrat_date 2023-02-15 Close